{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:34:48Z","timestamp":1780468488081,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jacl.2021.09.052","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T08:56:27Z","timestamp":1634028987000},"page":"782-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-6781","authenticated-orcid":false,"given":"Carl E.","family":"Orringer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Blaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6927-7783","authenticated-orcid":false,"given":"Neil J.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jacl.2021.09.052_bib0001","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.jacl.2021.09.052_bib0002","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"9542","key":"10.1016\/j.jacl.2021.09.052_bib0003","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.jacl.2021.09.052_bib0004","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacl.2021.09.052_bib0005","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009217.pub2","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"9841","key":"10.1016\/j.jacl.2021.09.052_bib0007","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Cholesterol Treatment Trialists","year":"2012","journal-title":"Lancet"},{"issue":"9976","key":"10.1016\/j.jacl.2021.09.052_bib0008","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"issue":"9435","key":"10.1016\/j.jacl.2021.09.052_bib0009","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jacl.2021.09.052_bib0010","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1161\/CIRCULATIONAHA.117.027966","volume":"136","author":"Vallejo-Vaz","year":"2017","journal-title":"Circulation"},{"issue":"10170","key":"10.1016\/j.jacl.2021.09.052_bib0011","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jacl.2021.09.052_bib0012","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2021.09.052_bib0013","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary Prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation,"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201196","article-title":"Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease","volume":"14","author":"Hope","year":"2019","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.jacl.2021.09.052_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The statin-associated muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drug Ther"},{"issue":"10","key":"10.1016\/j.jacl.2021.09.052_bib0016","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2021.09.052_bib0017","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0018","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.atherosclerosis.2015.06.049","article-title":"Statin-associated muscle symptoms EAS consensus panel paper focuses on this neglected patient group","volume":"242","author":"Stock","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.jacl.2021.09.052_bib0019","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2021.09.052_bib0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5\u00a0mg and 10\u00a0mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2021.09.052_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2021.09.052_bib0022","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"9965","key":"10.1016\/j.jacl.2021.09.052_bib0023","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"43","key":"10.1016\/j.jacl.2021.09.052_bib0024","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"issue":"10059","key":"10.1016\/j.jacl.2021.09.052_bib0025","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jacl.2021.09.052_bib0026","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1161\/CIRCULATIONAHA.118.036846","article-title":"Trust the blinded randomized evidence that Statin Therapy rarely causes symptomatic side effects","volume":"138","author":"Peto","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0027","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacl.2021.09.052_bib0028","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","article-title":"Nonspecific medication side effects and the nocebo phenomenon","volume":"287","author":"Barsky","year":"2002","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jacl.2021.09.052_bib0029","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jacl.2021.09.052_bib0030","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2021.09.052_bib0031","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"issue":"24","key":"10.1016\/j.jacl.2021.09.052_bib0032","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2018.11.005","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology","volume":"73","author":"Lloyd-Jones","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacl.2021.09.052_bib0033","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.jacl.2021.09.052_bib0034","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.jacc.2020.10.021","article-title":"Impact of plaque burden versus stenosis on ischemic events in patients with coronary atherosclerosis","volume":"76","author":"Mortensen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jacl.2021.09.052_bib0035","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines: MESA (Multi-Ethnic Study of Atherosclerosis)","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2021.09.052_bib0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2016.03.022","article-title":"CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA\/ACC primary prevention guidelines","volume":"10","author":"Mahabadi","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jacl.2021.09.052_bib0037","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.10.058","article-title":"Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment","volume":"67","author":"Yeboah","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacl.2021.09.052_bib0038","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jacc.2016.05.084","article-title":"A simple disease-guided approach to personalize ACC\/AHA-recommended statin allocation in elderly people: the BioImage study","volume":"68","author":"Mortensen","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0039","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018342","article-title":"Coronary artery calcium score-directed primary prevention with statins on the basis of the 2018 American College of Cardiology\/American Heart Association\/Multisociety Cholesterol Guidelines","volume":"10","author":"Taron","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.jacl.2021.09.052_bib0040","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jacc.2010.06.029","article-title":"Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study","volume":"56","author":"Elias-Smale","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"9792","key":"10.1016\/j.jacl.2021.09.052_bib0041","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0140-6736(11)60784-8","article-title":"Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study","volume":"378","author":"Blaha","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacl.2021.09.052_bib0042","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.mayocp.2020.01.016","article-title":"HOPE for rational statin allocation for primary prevention: a coronary artery calcium picture is worth 1000 words","volume":"95","author":"Orringer","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"38","key":"10.1016\/j.jacl.2021.09.052_bib0043","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacl.2021.09.052_bib0044","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.jacl.2021.09.052_bib0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem","year":"2011","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jacl.2021.09.052_bib0046","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2021.09.052_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jacl.2020.12.005","article-title":"The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction","volume":"15","author":"Orringer","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.jacl.2021.09.052_bib0048","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jcmg.2017.01.030","article-title":"The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis","volume":"10","author":"Gupta","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"25","key":"10.1016\/j.jacl.2021.09.052_bib0049","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of statins on cardiovascular outcomes following coronary artery calcium scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2021.09.052_bib0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M15-1241","article-title":"Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study","volume":"164","author":"Miglioretti","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.jacl.2021.09.052_bib0051","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jcmg.2017.04.014","article-title":"Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC\/AHA cholesterol management guidelines: a cost-effectiveness analysis","volume":"10","author":"Hong","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"10.1016\/j.jacl.2021.09.052_bib0052","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamacardio.2020.1240","article-title":"Cost-effectiveness of contemporary statin use guidelines with or without coronary artery calcium assessment in African American Individuals","volume":"5","author":"Spahillari","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2021.09.052_bib0053","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jacc.2020.06.077","article-title":"No-charge coronary artery calcium screening for cardiovascular risk assessment","volume":"76","author":"Al-Kindi","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421002518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421002518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:04Z","timestamp":1761831364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287421002518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1933287421002518"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2021.09.052","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2021.09.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}